Arkadiusz Dudek, M.D., Ph.D.

Dr Dudek is an Assistant Professor of Medicine and Director of the Clinical Trial Office in the Hematology, Oncology and Transplantation (HOT) Division.

Dr. Dudek received his M.D. in 1989 from the Medical Academy, University of Warsaw, Poland. He received internal medicine residency training in Harrisburg, Pennsylvania and subspecialty training in Hematology, Oncology and Transplantation at the University of Minnesota. He received his Ph.D. from Military Medical Academy of Warsaw in 1998. He then joined the Faculty in 1997.

Dr. Dudek's clinical interest is focused on the management of thoracic malignancies, but includes the treatment of malignant hematologic disorders, malignant melanoma, kidney cancer and blood and marrow transplantation. His clinical research interests includes phase I and II clinical trials in solid tumors. His laboratory research is focused on cancer angiogenesis.

Selected Publications

Dudek AZ, Pennell CA, Decker TD, Young TA, Key NS, Slungaard A. Platelet Factor 4 Binds To Glycanated Forms Of Thrombomodulin And To Protein C; A Potential Mechanism for Enhancing a Generation of Activated Protein C.  J Biol Chem 1997; 272:31785-92.

Gupta P, Oegema TR, Jr, Brazil JJ, Dudek AZ, Slungaard A, Verfaillie CM. Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche.  Blood 1998; 92:4641.

Gupta P, Oegema T, Brazil J, Dudek A, Slungaard A, Verfaillie C. Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: Requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins.  Blood 2000; 95:147.

Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow.  J Clin Invest 2002; 109:337-346.

Rocha-Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR. Irinotecan plus gemcitabine induces both radiographic and CAS 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.  J Clin Oncol 2002; 20:1182-1191.

Dudek AZ, Nesmelova I, Mayo K, Verfaillie CM, Pitchford S, Slungaard A.  Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: Novel mechanisms for modulation of hematopoiesis.  Blood 2003; 101:4687-4694.

Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ.  Bronchiolitis obliterans in chronic graft-versus-host disease: Analysis of risk factors and treatment outcomes.  Biol Blood Marrow Transplant 2003; 9:657-666.

Nesmelova IV, Sham Y, Dudek AZ, van Eijk LI, Wu G, Slungaard A, Mortari F, Griffioen AW, Mayo KH.  Platelet factor 4 and interleukin 8 CXC-chemokine heterodimer formation modulates function at the quarternary structural level.  J Biol Chem 2005; 280:4948-58.

Dudek AZ, Lesniewski-Kmak K, Bliss RL, Brunstein C, Condon DL, Kratzke RA. Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer. Lung. 2005; 183:43-52.

Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer. 2006; 51:89-96. 

Arodz T, Yuen DA, Dudek AZ. Ensemble of linear models for predicting drug properties.  J Chem Inf Model. 2006; 46:416-23. 

Dudek AZ, Mahaseth H. Hematopoietic stem cell transplant-related airflow obstruction. Curr Opin Oncol. 2006; 18:115-9.

Dudek AZ, Arodz T, Galvez J.  Computational methods in developing quantitative structure-activity relationships (QSAR): a review. Comb Chem High Throughput Screen. 2006; 9:213-28.